TN2012000248A1 - Novel spiropiperidine compounds - Google Patents
Novel spiropiperidine compoundsInfo
- Publication number
- TN2012000248A1 TN2012000248A1 TNP2012000248A TN2012000248A TN2012000248A1 TN 2012000248 A1 TN2012000248 A1 TN 2012000248A1 TN P2012000248 A TNP2012000248 A TN P2012000248A TN 2012000248 A TN2012000248 A TN 2012000248A TN 2012000248 A1 TN2012000248 A1 TN 2012000248A1
- Authority
- TN
- Tunisia
- Prior art keywords
- spiropiperidine compounds
- novel spiropiperidine
- novel
- compounds
- compound
- Prior art date
Links
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26518109P | 2009-11-30 | 2009-11-30 | |
| PCT/US2010/057359 WO2011066183A1 (en) | 2009-11-30 | 2010-11-19 | Novel spiropiperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2012000248A1 true TN2012000248A1 (en) | 2013-12-12 |
Family
ID=43384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2012000248A TN2012000248A1 (en) | 2009-11-30 | 2012-05-22 | Novel spiropiperidine compounds |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8822486B2 (enExample) |
| EP (1) | EP2507228B1 (enExample) |
| JP (1) | JP5709889B2 (enExample) |
| KR (1) | KR101410103B1 (enExample) |
| CN (1) | CN102648195B (enExample) |
| AR (1) | AR078948A1 (enExample) |
| AU (1) | AU2010324987B2 (enExample) |
| BR (1) | BR112012012903A2 (enExample) |
| CA (1) | CA2781292C (enExample) |
| CL (1) | CL2012001321A1 (enExample) |
| CR (1) | CR20120296A (enExample) |
| DO (1) | DOP2012000139A (enExample) |
| EA (1) | EA020507B1 (enExample) |
| EC (1) | ECSP12011930A (enExample) |
| ES (1) | ES2526568T3 (enExample) |
| GT (1) | GT201200164A (enExample) |
| IL (1) | IL219594A0 (enExample) |
| MA (1) | MA33840B1 (enExample) |
| MX (1) | MX2012006233A (enExample) |
| NZ (1) | NZ600203A (enExample) |
| PE (1) | PE20121474A1 (enExample) |
| PH (1) | PH12012501052A1 (enExample) |
| TN (1) | TN2012000248A1 (enExample) |
| TW (1) | TW201141866A (enExample) |
| WO (1) | WO2011066183A1 (enExample) |
| ZA (1) | ZA201203055B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| CN104710381A (zh) | 2009-12-25 | 2015-06-17 | 持田制药株式会社 | 新的3-羟基-5-芳基异噻唑衍生物 |
| US9040525B2 (en) | 2010-10-08 | 2015-05-26 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| BR112013027883A2 (pt) | 2011-04-27 | 2017-08-08 | Mochida Pharm Co Ltd | novo derivado de 1-óxido de 3-hidroxiisotiazol |
| US9072758B2 (en) | 2011-04-28 | 2015-07-07 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| ES2690145T3 (es) * | 2013-03-14 | 2018-11-19 | Janssen Pharmaceutica Nv | Agonistas de GPR120 para el tratamiento de diabetes de tipo 2 |
| US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
| US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| EP3102198B1 (en) | 2014-02-06 | 2020-08-26 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| CA2520114A1 (en) | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| JP2007510662A (ja) | 2003-11-04 | 2007-04-26 | エリクシアー ファーマシューティカルズ， インコーポレイテッド | 治療化合物およびその使用 |
| AU2005220728B2 (en) | 2004-02-27 | 2009-08-06 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| WO2006028239A1 (ja) * | 2004-09-07 | 2006-03-16 | Banyu Pharmaceutical Co., Ltd. | カルバモイル置換スピロ誘導体 |
| JP2009543860A (ja) * | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
| US20090247560A1 (en) * | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| PL2125827T3 (pl) * | 2006-12-29 | 2011-04-29 | Hoffmann La Roche | Pochodne azaspiro |
| ES2446419T3 (es) * | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| RU2490250C2 (ru) * | 2007-10-26 | 2013-08-20 | Джапан Тобакко Инк. | Спиросоединения и их фармацевтическое применение |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/en not_active Ceased
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/en active Active
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 PH PH1/2012/501052A patent/PH12012501052A1/en unknown
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active Expired - Fee Related
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 CA CA2781292A patent/CA2781292C/en not_active Expired - Fee Related
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA33840B1 (fr) | 2012-12-03 |
| EP2507228A1 (en) | 2012-10-10 |
| CR20120296A (es) | 2012-07-16 |
| CA2781292C (en) | 2014-04-22 |
| KR101410103B1 (ko) | 2014-06-25 |
| GT201200164A (es) | 2014-02-27 |
| PH12012501052A1 (en) | 2013-02-04 |
| CL2012001321A1 (es) | 2013-11-15 |
| JP5709889B2 (ja) | 2015-04-30 |
| ES2526568T3 (es) | 2015-01-13 |
| AU2010324987B2 (en) | 2014-01-30 |
| AU2010324987A1 (en) | 2012-07-26 |
| EA020507B1 (ru) | 2014-11-28 |
| TW201141866A (en) | 2011-12-01 |
| AR078948A1 (es) | 2011-12-14 |
| ECSP12011930A (es) | 2012-07-31 |
| US8822486B2 (en) | 2014-09-02 |
| CA2781292A1 (en) | 2011-06-03 |
| JP2013512277A (ja) | 2013-04-11 |
| EP2507228B1 (en) | 2014-11-05 |
| ZA201203055B (en) | 2013-09-25 |
| IL219594A0 (en) | 2012-06-28 |
| WO2011066183A1 (en) | 2011-06-03 |
| PE20121474A1 (es) | 2012-11-05 |
| KR20120088770A (ko) | 2012-08-08 |
| NZ600203A (en) | 2013-09-27 |
| DOP2012000139A (es) | 2012-08-15 |
| CN102648195A (zh) | 2012-08-22 |
| BR112012012903A2 (pt) | 2017-03-01 |
| US20120220616A1 (en) | 2012-08-30 |
| MX2012006233A (es) | 2012-07-03 |
| EA201290416A1 (ru) | 2012-11-30 |
| CN102648195B (zh) | 2015-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2012000248A1 (en) | Novel spiropiperidine compounds | |
| TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
| SG178952A1 (en) | Chemical compounds | |
| MY149648A (en) | Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
| MX2010002419A (es) | (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento. | |
| MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
| WO2010108074A3 (en) | Inhibitors of pi3 kinase | |
| MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
| TN2013000434A1 (en) | Novel imidazole derivatives useful for the treatment of arthritis | |
| SG179034A1 (en) | 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes | |
| MY160392A (en) | Triptolide prodrugs | |
| SG194463A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
| MX2011008289A (es) | Tabletas para terapia combinada. | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| JO2979B1 (en) | Cyclopropyl compounds | |
| WO2012164055A3 (en) | New compounds, synthesis and use thereof in the treatment of pain | |
| NZ589911A (en) | Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof | |
| TN2010000397A1 (en) | Heterocyclic compounds | |
| WO2012008765A3 (ko) | 암 치료 또는 예방용 약학 조성물 | |
| UA87608C2 (uk) | Спосіб отримання ціанометилпіримідинів | |
| UA60840U (ru) | Способ лечения больных сахарным диабетом | |
| TN2010000353A1 (en) | Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria | |
| JO2775B1 (en) | 3-indazolil 4-pyridyl isothiazole |